Connect your AI

Aclaris Therapeutics ACRS Gross Profit

Discontinued — last reported Q1 '26

Gross Profit at other companies

Eton Pharmaceuticals, Inc.ETON

$14.74M+49.4%

Kura OncologyKURA

$18M—

IncyteINCY

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Revenue$2.0M+37.2%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Calculated from Aclaris Therapeutics’s reported figures.

$2.0Mtotal revenue−$395.0Ktotal cost of revenue=$1.6M

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Aclaris Therapeutics's gross profit?: Aclaris Therapeutics (ACRS) reported gross profit of $1.6M in Q1 2026.
How has Aclaris Therapeutics's gross profit changed year-over-year?: Aclaris Therapeutics's gross profit increased by 68.7% year-over-year, from $949K to $1.6M.
What is the long-term trend for Aclaris Therapeutics's gross profit?: Over 4 years (2021 to 2025), Aclaris Therapeutics's gross profit has grown at a 29.4% compound annual growth rate (CAGR), from $2.05M to $5.74M.
What does gross profit mean?: Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.